Just ONE tablet delivers 450 mg bupropion each day.

You can titrate to higher doses without adding more pills. Patients can be titrated up to Forfivo XL 450 mg once daily if they have been taking 300 mg per day of bupropion for at least 2 weeks and require a dosage of 450 mg per day.

Forfivo XL® provides a once-daily, bupropion 450 mg dose in a single tablet:
  • Indicated for the treatment of major depressive disorder
  • Proven bioequivalent to Wellbutrin XL®1
  • One Forfivo XL 450 mg tablet per day is equivalent to Wellbutrin XL 3 X 150 mg
Maintenance Therapy:
  • It is not known whether the 450 mg dose needed to achieve initial response is needed for maintenance treatment
  • Patients should be periodically reassessed to determine the need for a maintenance treatment and the appropriate dose for such patients
Therapy Initiation:
  • Patients currently treated with other bupropion products may be switched to Forfivo XL if they are receiving:
    • 450 mg/day
    • 300 mg/day for a least two weeks and requiring a dose increase to 450 mg/day
  • Do not initiate bupropion therapy with Forfivo XL because 450 mg is the only available dosage strength. Use another lower dose bupropion product for initial dose titration.
Rx Savings Program:
  • Rx Savings Program will automatically limit 30-day Rx cost to $28 for most commercial drug plan patients*
    • Some patients may still need a physical copay savings card to reduce their cost
    • Copay cards can be downloaded on this page

Download the Full Prescribing Information, including Boxed Warning, and Medication Guide.

*Eligibility requirements:
To the Patient: Where third-party reimbursement covers a portion of your prescription, this offer is valid only if your out-of-pocket expense for each prescription exceeds $28, with a maximum savings benefit of up to $175 for ≤ 59 tablets; up to $350 for 60-89 tablets; or up to $525 for ≥ 90 tablets. Offer is not valid for prescriptions being fully or partially reimbursed under Medicaid, a Medicare drug benefit plan, or other federal or state program (such as medical assistance programs). The patient is responsible for reporting receipt of this offer to any health plan, health insurer, or third-party payer as may be required. By using this offer you agree that you will not submit a claim for the prescription to any government payer. If any part of your prescription is paid for by a nongovernmental third-party payer, you attest to having disclosed this offer to your third-party payer. The use of this card is subject to applicable state and federal law. Void where prohibited or restricted. Offer expires upon program termination by Edgemont Pharmaceuticals. Edgemont Pharmaceuticals reserves the right to rescind, revoke, or amend this program without notice.

1Godfrey, AR. Single dose crossover comparative bioavailability study of bupropion hydrochloride 450 mg extended release tablets and Wellbutrin XL® 150 mg extended release tablets in healthy male volunteers under fasting and fed conditions [clinical study report]. Laval, QC: Algorithme Pharma Inc; 2011.

FORFIVO XL® is a registered trademark of IntelGenx Corp. Wellbutrin XL is a registered trademark of GlaxoSmithKline.